Feature|Videos|November 16, 2026

Build, Buy, or Rent: Moving AI Beyond the Pilot Stage

Key Takeaways

  • Understand the criteria for whether to rent, build, or buy AI solutions.
  • Learn how to evaluate agency partners on original thinking, healthcare expertise, and measurable business impact.
SHOW MORE

Experts weigh in about how leaders should decide where to source artificial intelligence (AI) solutions and why so many pilots never reach scale.

With new AI solutions emerging at a rapid pace, commercial leaders face ongoing decisions about which capabilities to build, which to buy, and where to partner. Shankar Narayanan, CEO of Real Chemistry, Zoë Lazarre, CMO of Genetech, and Claudia Ciciliano, VP Digital Strategy & Product Operations at Bayer share how their views on these choices continue to evolve. Lazarre compares the steady stream of new tools to a new sports car arriving every month; she emphasizes that teaching marketers to drive well matters more than acquiring every new model. Proprietary assets, such as customer understanding and field insights, should remain owned. Ciciliano describes a build, buy, or rent approach in which building is the preference, renting allows teams to move quickly and learn before deciding whether to build, and buying makes sense when a tool already fits within an existing workflow.

The panelists agree the agency model is changing. As AI makes content creation more accessible, agencies are expected to differentiate through original thinking, healthcare expertise, and demonstrable business impact. Narayanan outlines three shifts from the agency perspective: moving from services toward solutions supported by underlying technology, shifting commercial models from billable hours toward accountability for outcomes and deliverables, and rethinking talent development as AI compresses the traditional apprenticeship that shaped earlier generations of marketers.

Addressing why most AI pilots fail to scale, Ciciliano says that AI is an organizational transformation rather than a technology project. She describes three equally important levers—impact and growth, productivity, and talent development—and notes that leaders must commit capacity during an initial surge of effort before the value is realized.


Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.